Clinical trial · Observational
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to analyze the impact on three years survival of an enhanced recovery program (PRI) after radical surgert for adenocarcinoma gastric cancer. As secondaries objectives, we propose to analyze comparing survival distributions between patient groups (ERAS/no ERAS) and the relationship between the ERAS program and early incorporation into oncology therapies (RIOT). It is proposed to review the medical records of oncology patients included in POWER 4 (as already foreseen in that study), with the aim of performing a 3-year follow-up. To create comparable treatment and control groups, the Propensity Index method will be used. To study each variable, multivariate regression will be used. Kaplan-Meier will be used for survival and the log-rank test for comparisons. Significance will be considered if p \<0.05 (two tails).
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of Stomach | Gastric Adenocarcinoma | ALIAS | 0.90 |
| Chemotherapy, Adjuvant | — | UNRESOLVED | — |
| Critical Pathways | — | UNRESOLVED | — |
| Enhanced Recovery After Surgery (ERAS) Protocol | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Retrospective Studies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gastric surgery and ERAS protocol | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Overall Survival
- timeFrame
- 3 years
- description
- Patients alive from surgery to the last control
- measure
- Disease-free surviva
- timeFrame
- 3 years
- description
- Number of patients alive and without cancer recurrence from the intervention period until the end of follow-up
- measure
- Time to disease recurrence
- timeFrame
- 3 years
- description
- Detected from the day of the intervention until the end of follow-up
- measure
- Time to return to intended oncologic treatment (RIOT)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- All patients over 18 years of age who underwent elective gastric cancer surgery in POWER4 Exclusion Criteria: \- Non oncological surgery, refusal of the centers to participate.
References
Publications (1)
- DERIVEDRipolles-Melchor J, Abad-Motos A, Leon-Bretscher A, Espinosa AV, Amoza-Pais S, Herrero-Bogajo ML, Abad-Gurumeta A, de-la-Plaza-Llamas R, Galan-Menendez P, Zorrilla-Vaca A, Gonzalez-Lopez R, Navarro-Perez R, Jimenez-Vinas C, Parreno-Manchado FC, Ruiz Escobar A, Concepcion-Martin V, Paseiro-Crespo G, Acosta-Merida MA, Puech-de-Oriol M, Mayo-Ossorio MA, Garcia-Nebreda M, Chaveli-Diaz C, Fernandez-Valdes-Bango P, Torres-Alfonso JR, Barragan-Serrano C, Aldecoa C; POWER4 Investigators Group. Disease-free survival after gastrectomy is not influenced by ERAS adherence. Anaesth Crit Care Pain Med. 2026 Apr;45(2):101661. doi: 10.1016/j.accpm.2025.101661. Epub 2025 Oct 30. PMID 41175931